MONROE, N.C. — Monoclonal antibody infusion used to treat COVID-19 in high-risk patients is effective but difficult to administer.
The FDA approved the treatment for emergency use only.
“These proteins are specifically designed to neutralize COVID by binding to the virus and preventing it from entering the human cell,” said Benjamin Karsai, with Monroe Biomedical Research.
In the video at the top of this webpage, anchor Genevieve Curtis reports on a lab in Monroe that is attempting to make the treatment more accessible.
Cox Media Group